Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline
Vaccine Efforts Caused No Productivity Blip, Says R&D Head
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.
